Search
Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model
We identified previously unidentified gene fusions involving the MET oncogene in pediatric glioblastoma
The trivalent inactivated influenza vaccine is safe, immunogenic, provides clinical protection and should be administered annually to immunosuppressed children receiving treatment for cancer
This study investigates the different patterns of relapse in patients with central nervous system mixed malignant germ cell tumors - treated with chemotherapy.
This study investigated the relapse and outcome patterns of patients with central nervous system mixed malignant germ cell tumors treated with chemotherapy-only
Medulloblastoma, the most common pediatric malignant brain tumor, consists of at least four distinct molecular subgroups.
Rare childhood cancers have not benefited to the same extent from the gains that have been made for their frequently occurring counterparts.
Medulloblastoma is the most common form of malignant paediatric brain tumour and is the leading cause of childhood cancer related mortality.
Nick Gottardo MBChB FRACP PhD Head of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research
Medulloblastoma is the most common malignant paediatric brain tumour and a leading cause of cancer-related mortality and morbidity. Existing treatment protocols are aggressive in nature resulting in significant neurological, intellectual and physical disabilities for the children undergoing treatment. Thus, there is an urgent need for improved, targeted therapies that minimize these harmful side effects.